Advanced Medical Solutions Group Regulatory News (AMS)

6 Jun 2007 07:00

Advanced Medical Solutions Grp PLC06 June 2007 For Immediate Release 6 June 2007 Advanced Medical Solutions Group plc ("AMS" or "the Company") Trading Update Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company, today announces an update on current trading priorto its Annual General Meeting to be held at 11:00am today. Dr. Geoffrey Vernon, Chairman of Advanced Medical Solutions Group plc, stated: "I am pleased to advise that the strong start to the year reported in thePreliminary Results announced on 13 March 2007 has continued. The Company is ontrack to deliver maiden first half profits and continues to trade well in linewith market expectations for the full year 2007. "The outlook remains extremely positive. The organic business continues toperform well with our ActivHeal(R) woundcare range gaining wider acceptance inthe NHS, our presence in the dynamic silver alginate market broadening andKimberly-Clark launching InteguSeal* Microbial Sealant in the US. The Group'sfinancial position continues to improve allowing management to review potentialacquisitions to leverage its technology and distribution base". -- ENDS -- For further information, please contact: Advanced Medical Solutions Group plc +44 (0) 01606 545508Don Evans (Chief Executive Officer)Mary Tavener (Group Finance Director)www.admedsol.com Buchanan Communications +44 (0) 020 7466 5000Mark Court/Mary-Jane Johnson * Trademark of Kimberly-Clark Worldwide, Inc. (c) 2007 KCWW. Notes to Editors: Advanced Medical Solutions is a UK based company developing and providingleading edge technology to the $15 billion global woundcare market. Founded in 1991 and quoted on AIM, the Company is focused on the design,development, manufacture and sale of advanced woundcare dressings and productsfor closing wounds and sealing tissue. AMS provides a full range of advanced woundcare products for sale in hospital,nursing home and community care markets. The main indications are for chronicwounds such as ulcers and pressure sores. These products pioneer the concept ofmoist wound healing to allow wounds to heal faster and with less pain andscarring if they remain moist. They protect the wound, deal with tissue fluidsand provide an optimal environment for healing to occur. AMS' resources ensurea unique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove a product from design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products based uponcyanoacrylate adhesive technology which allow the closure of wounds followingtrauma or surgical incisions, or seal skin to protect against breakdown or woundinfection. These products address the emerging tissue adhesives and sealantssegment of the wound closure market. AMS' technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock Exchange